ADCs: Overcoming Analytical Challenges In Next-Gen Cancer Therapies

Antibody-Drug Conjugates (ADCs) represent a revolutionary approach in cancer treatment. But with innovation comes complexity. ADCs combine an antibody, a linker, and a cytotoxic drug — each component requiring precise analytical strategies to ensure product safety, efficacy, and consistency.

In this insightful white paper, we explore these critical challenges, focusing on the characterization, stability, and potency of each ADC component. From assessing antibody integrity and linker stability to evaluating payload potency and drug-to-antibody ratio (DAR), discover how a robust CMC strategy can accelerate your ADC development.

What You Will Learn:

• Key Analytical Challenges

Gain insights into the unique analytical challenges associated with each component of an ADC — antibody, linker, and payload — covering aspects like structural integrity, stability, and targeted delivery

• Critical Role of Drug-to-Antibody Ratio (DAR)

Understand the importance of maintaining a consistent DAR in ADC development to balance potency and minimize toxicity, including methods for accurate DAR measurement and distribution analysis

• Optimizing Cell-Based Bioassays

Learn about the role of cell-based bioassays in evaluating ADC potency, with tailored assay designs to account for biological variation, drug concentration, and target cell response.